Biosyent (Biosyent) Current Deferred Revenue : $0.10 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Biosyent Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Biosyent's current deferred revenue for the quarter that ended in Dec. 2023 was $0.10 Mil.

Biosyent Current Deferred Revenue Historical Data

The historical data trend for Biosyent's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent Current Deferred Revenue Chart

Biosyent Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Deferred Revenue

Get a 7-Day Free Trial

0.08

0.73

0.25

0.12

0.10

Biosyent Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Current Deferred Revenue	Get a 7-Day Free Trial															0.12	0.15	0.85	0.19	0.10

Biosyent Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Biosyent's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Biosyent (Biosyent) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (OTCPK:BIOYF) » Definitions » Current Deferred Revenue

Comparable Companies

Traded in Other Exchanges

RX:Canada

Address

2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1

Website

http://www.biosyent.com

Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.